Sentiment Analysis of the earnings transcript to help figure out if there are any bullish or bearish sentiments that could be gathered from it. We're doing ML and AI based analysis on the earnings call to get some more insights.
Please consider a small donation if you think this website provides you with relevant information
| Statement |
|---|
| Having said that, we're confident that we should be able to deliver data this year |
| We are very proud of our commercial effort for Sunosi and expect continued growth in 2024 |
| Now, we do think that the product should have a favorable placement in the treatment paradigm that complements solriamfetol and other treatment options |
| 2023 was another strong year for Axsome, built on focused commercial execution for our first-in-class marketed products and continued advancement and expansion of our industry-leading neuroscience pipeline |
| We've modeled various scenarios, and based on the success that we've had thus far, we feel very confident of our ability to be cash flow positive |
| We are very optimistic about Auvelity's growth prospects in 2024 and its long-term blockbuster potential |
| So more details to come, but we feel very confident that we'll be able to have an efficient selling effort based on the shared call points or most of the indications that exist in our pipeline as well as our on-market products |
| Clearly, there's significant unmet treatment need, and that gives us great confidence for the future with AXS-05 |
| But I think this is also really positive news for AXS-05 |
| However, AD agitation, we are confident that we should be able to have results this year |
| Axsome completed our first full-year as a commercial company by delivering strong performance for both of our on-market products |
| Anecdotal feedback from providers and patients continues to reinforce our belief that Auvelity and Sunosi are unique and differentiated treatment options in their respective indications and supports our growing confidence that Axsome is reshaping the treatment landscape for CNS conditions |
| 2023 was a strong year for Axsome |
| We expect continued revenue growth in 2024, aided by our completed sales force expansion for Auvelity and increasing awareness of our differentiated products |
| We made solid progress in the preparation of our NDAs for AXS-07 in migraine and AXS-14 in fibromyalgia |
| In addition, we observed meaningful traction within the primary care segment among both MDs and NPPAs as the early impact from our recent sales force expansion began to take hold with increased call activity in primary care offices |
| In addition, adopters note the positive impact of Auvelity has demonstrated on day-to-day patient functioning and its improvements in patient perceptions of quality of life |
| Axsome has established a strong commercial foundation to support continued Auvelity growth in 2024, with approximately 260 sales representatives calling on 44,000 health care providers and continued investment in our industry-leading digital-centric commercialization platform |
| We are well-positioned to accelerate our education and awareness objectives across the predominant depression treaters in the U.S |
| We've been very pleased with that investment so far |
| In a recent survey of Sunosi adopters, key attributes driving demand for the product cited by respondents include significant and sustained impact on the Epworth sleepiness scale, a market leading nine plus hours of wakefulness observed in Phase 3 clinical trials and significant improvement in patient-reported outcomes at week 12 |
| In closing, Axsome delivered compelling commercial performance in Q4 2023 as the optimization of our commercial infrastructure took shape and we completed our first full-year as a commercial company |
| This progress positions us to deliver on multiple, potentially value driving milestones throughout 2024 |
| But we are very pleased with the increased field force effort post-expansion |
| An enhanced brand story for 2024 has been created to augment provider perceptions of Auvelity and is anchored on Auvelity's key attributes |
| So we are seeing a meaningful improvement in terms of earlier line treatment |
| Auvelity performance in the quarter was primarily driven by specialists in psychiatry practices, with both Psychiatry MDs and nurse practitioners and physician assistants, or NPPAs contributing to robust growth in the quarter and over the course of 2023 |
| Auvelity has a well-established safety and tolerability profile that includes low impact on weight and sexual dysfunction and no risk of movement disorders or extrapyramidal symptoms |
| Congrats on a great year of commercialization |
| And so we are very optimistic about continued investment in consumer advertising, and we are assessing additional investments at the moment |
| Statement |
|---|
| Q1 typically has a negative seasonality effect on GTN |
| This performance contrasts with a decline of 1% for the overall antidepressant market during the same period |
| And I do think it's a little premature to suggest that it's a good analog for AXS-05 |
| I don't know if it's patient enrollment forms or claims, but given that's a massive market, I'm a little surprised that given the TRx move that we've seen, that it's being characterized as an inflection |
| Net loss for the fourth quarter of 2023 was $98.7 million, or $2.08 per share, compared to a net loss of $61.2 million or $1.41 per share for the comparable period in 2022 |
| Net loss was $239.2 million, or $5.27 per share for the full-year of 2023 compared to a net loss of $187.1 million, or $4.60 per share for the full-year of 2022 |
| So sorry about that |
Please consider a small donation if you think this website provides you with relevant information